Archives: News

Oncolytics Biotech is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype – turning “cold” tumors “hot” – through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents. Oncolytics is currently conducting and planning additional studies in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer.

Founded in San Francisco in 1988, Domann opened its San Diego office in 2001 and thanks the companies and individuals in the community who we served and supported.

SAN DIEGO–(BUSINESS WIRE)–Lengo Therapeutics, a biopharmaceutical company developing novel precision medicines targeting driver mutations in oncology, today announced the appointment of Diana Hausman, M.D., as Chief Medical Officer. In this role, Dr. Hausman will be responsible for leading clinical development and strategy for the Company.

“Diana brings invaluable experience and expertise to our team, as we advance our pipeline of best-in-class precision therapeutics for treatment-resistant cancers,” said Helen Jenkins, Chief Executive Officer, Lengo Therapeutics. “Her experience leading several clinical programs in oncology from first in human through to registrational studies is incredibly relevant, as we prepare for our next stage of growth.”

“I am excited to join the incredible team at Lengo, and work alongside a world-class team of scientists and leaders in kinase inhibition developing transformative therapeutics in oncology,” said Dr. Hausman. “I look forward to leveraging my extensive clinical experience in the biotechnology industry to lead the continued development of Lengo’s pipeline for cancer patients with unmet medical needs.”

Dr. Diana Hausman is a board-certified medical oncologist with over 20 years of clinical drug development experience. Prior to joining Lengo, she served as Chief Medical Officer for Zymeworks Inc. for 5 years. While at Zymeworks, Dr. Hausman oversaw all aspects of clinical development, including advancement of the HER2-targeted biparatopic antibody zanidatamab from initial IND to ongoing global Phase 2 and pivotal studies, including breakthrough therapy designation for biliary tract cancer.

Dr. Hausman was previously CMO at Oncothyreon Inc where she oversaw the Phase 1b and early Phase 2 clinical program for the HER2-targeted small molecule, tucatinib. She has also held positions of increasing responsibility at ZymoGenetics, Berlex, and Immunex, working across multiple indications, including oncology, hematology, hepatitis C and autoimmune disease. Dr. Hausman received her internal medicine and specialty training in hematology and medical oncology at the University of Washington. She received her M.D. degree from the University of Pennsylvania, Philadelphia, PA, and an A.B. in biology from Princeton University.

About Lengo Therapeutics

Lengo Therapeutics is a biopharmaceutical company committed to developing novel, precision medicines targeting driver mutations in oncology. Lengo has assembled a team of scientists and industry leaders with extensive expertise in kinase biology, covalent drug-target technology and oncology drug development. The company’s vision is to develop a pipeline of investigational candidates that can offer benefit to patients with cancers harboring driver mutations. Lengo Therapeutics is based in San Diego. For more information, please visit www.lengotx.com.

Funding supports commercial launch of novel fluorescence image-guided surgery system

MADISON, WISCONSIN, April 30, 2021, BusinessWire – OnLume Surgical, a Wisconsin-based medical device company developing novel imaging systems for use during surgery, announced the completion of its Series A funding to assist its plans for commercial launch.

OnLume raised over $7 Million in this financing, adding to a $2 Million Phase II SBIR grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH), awarded in late 2020.

“The completion of the Series A financing, plus the Phase II grant from NCI, provides the resources for important milestones ahead during the next 24 months,” stated James A. Bowman, OnLume’s Chief Executive Officer. “These activities include commercial launch into our first market vertical and progress on other market opportunities.”

“This achievement highlights the promise of OnLume’s patented technology in the field of fluorescence-guided surgery, which illuminates critical anatomy in real-time during surgery to optimize precision, helping to improve patient outcomes, reduce morbidity and reduce costs,” added Mr. Bowman.

This Series A financing was led by Cambridge Investment Group (Luzich Partners LLC) and participation included WARF Ventures (Wisconsin Alumni Research Foundation) and Wisconsin Investment Partners (WIP).

About OnLume Inc.: OnLume Inc. is a surgical device company which recently received its first FDA regulatory clearance to bring its fluorescence-guided surgery (FGS) imaging system to market. The technology is cleared for fluorescence imaging of blood flow and tissue perfusion before, during and after vascular, gastrointestinal, organ transplant, plastic, reconstructive and microsurgeries.

OnLume is developing further applications of its imaging platform, including FGS for cancer surgery in which tumor-specific drugs could deliver fluorescent agents to cancer cells to help surgeons identify residual cancer tissue that are otherwise invisible.

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.

Research referenced in this press release is supported by the National Cancer Institute of the National Institutes of Health under the award number R44CA206754. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

OnLume Contact Information:
James A. Bowman
Chief Executive Officer
OnLume Surgical
jim.bowman@onlume.com
https://www.onlume.com